Sirolimus animal studies vs human evidence: what we know

Last updated 2026-07-27

What's the actual difference between sirolimus and rapamycin?

None, chemically. Sirolimus is the generic drug name; rapamycin is the original name given to the compound isolated from Streptomyces hygroscopicus, a bacterium found in soil on Easter Island (Rapa Nui) in the 1970s ^[1]. When you see "rapamycin" in a longevity podcast and "sirolimus" on a pharmacy label, it's the same molecule. Same structure, same mechanism, same drug. The naming split exists for historical and marketing reasons. Wyeth developed it as an immunosuppressant and sold it under the brand name Rapamune, using the generic name sirolimus, after Pfizer acquired Wyeth ^[2]. "Rapamycin" stuck in scientific literature and among longevity researchers, so both names are used interchangeably depending on whether you're reading a transplant journal or a biohacking forum. There's no separate "rapamycin for longevity" formulation. If a compounding pharmacy is filling a longevity prescription, it's making the same active pharmaceutical ingredient found in FDA-approved sirolimus.

What does the mouse data actually show?

The strongest evidence anywhere for rapamycin extending lifespan comes from mice, and it's genuinely good data, not a fringe finding. The National Institute on Aging's Interventions Testing Program (ITP), running since 2004 across three labs (Jackson Laboratory, University of Michigan, University of Texas Health Science Center San Antonio), has tested rapamycin in multiple independent cohorts of genetically heterogeneous mice, the closest thing to a randomized controlled trial design that exists in aging biology ^[3]. The first published ITP result, in 2009, found that rapamycin fed starting at 600 ppm in food beginning at 20 months of age (roughly equivalent to a 60-year-old human) extended median lifespan by 9% in males and 13% in females, even though dosing started late in life ^[4]. That was a big deal in the field: it suggested you didn't need to start young to get a benefit. Later ITP cohorts starting rapamycin at 9 months of age, with higher doses, showed larger effects, up to around 23% in males and 26% in females in some cohorts, according to pooled ITP data summarized by the University of Michigan's ITP program page ^[5]. This isn't a single lucky study. Rapamycin is the only compound the ITP has tested that has extended lifespan in every cohort, in both sexes, across repeated independent trials. That reproducibility is exactly why it's the anchor compound for the whole mTOR-and-longevity story. Other tested compounds (resveratrol, metformin, aspirin, and dozens more) have mostly failed to replicate or shown weak, sex-specific, or inconsistent effects. Rapamycin has also extended lifespan in other model organisms: yeast, worms (C. elegans), and fruit flies (Drosophila), across a range of independent labs, which is part of why the mechanism (mTOR inhibition slowing nutrient-sensing pathways tied to aging) is taken seriously rather than dismissed as a mouse-only quirk ^[6].

Has rapamycin ever extended lifespan in humans?

No. There is no completed human trial, anywhere, that has measured whether rapamycin extends human lifespan. This is the single most important fact in this entire topic and it doesn't change no matter how compelling the mouse data or the mTOR biology looks. Lifespan trials in humans are extraordinarily hard to run. A trial designed to detect a lifespan effect in people would need many thousands of participants followed for decades, cost hundreds of millions of dollars, and face the ethical and practical problem of giving a chronic immunosuppressant to healthy people for years without a clear surrogate endpoint regulators accept. Nobody, not a university, not the NIA, not a pharmaceutical company, has run one. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity) is the closest thing to a human aging trial currently active, and it measures markers like frailty index and biological age proxies, not lifespan, over roughly 12-48 months ^[7]. That's a meaningfully different question than "does this make people live longer." What we do have from humans: decades of pharmacokinetic and safety data from transplant medicine, where sirolimus has been FDA-approved since 1999 for preventing organ rejection at continuous, higher doses than longevity users take ^[8]. We also have a handful of small, short-duration studies in healthy or older adults looking at immune function and biomarkers, not survival. The most cited is a 2014 Novartis-funded study (using an mTOR inhibitor closely related to rapamycin, RAD001/everolimus) that found improved influenza vaccine response in adults over 65 taking low doses for 6 weeks, which got a lot of longevity-world attention as indirect evidence that mTOR inhibition could improve immune function in older people rather than only suppressing it ^[9]. That is interesting and worth knowing. It is not a lifespan study, and it used a different drug.

Why can't we just apply the mouse dosing to humans?

Because mouse and human pharmacology don't translate on a simple mg/kg basis, and because the mouse studies used continuous daily dosing in food, which is a different exposure pattern than the intermittent, once-weekly or twice-weekly protocols most longevity clinicians actually prescribe off-label. Mice in the ITP studies received rapamycin continuously through their diet at doses (in ppm of chow) calibrated to their body size and metabolism. Translating that to a human dose isn't a matter of simple scaling; body surface area conversions, differences in drug metabolism (rapamycin is metabolized by CYP3A4 and is a substrate of P-glycoprotein, with known variability across individuals), and the fact that mice were dosed continuously all complicate the picture ^[10]. Off-label longevity dosing in humans is almost always intermittent (commonly weekly or every-other-week, at doses of roughly 3-10mg depending on the protocol), a pattern chosen deliberately to try to hit the target of interest (mTORC1) hard while giving mTORC2 and immune function more room to recover between doses. That intermittent-dosing logic comes from later mouse studies (Bitto et al., 2016, in eLife) showing that intermittent, high-dose rapamycin in mice extended lifespan and improved some measures of healthspan without the continuous immunosuppression seen with daily dosing ^[11]. It's a reasonable hypothesis. It has not been tested against continuous dosing in a human lifespan trial. If you're working out doses and schedules for yourself, our Sirolimus Rx dosage guide and dosage calculator walk through how clinicians translate these protocols, but everything downstream of the mouse data here is extrapolation, not proof.

What are the real risks of off-label rapamycin use?

The risk profile is well characterized because sirolimus has been used at continuous, higher doses in transplant patients for over two decades, even though the intermittent low-dose longevity pattern hasn't been studied on its own long-term safety timeline. Immunosuppression is the core mechanism-based risk. Sirolimus works partly by dampening mTOR-driven immune cell proliferation, which is exactly why it prevents organ rejection and exactly why chronic use raises infection risk. The FDA label for Rapamune warns about increased susceptibility to infection and lists sepsis and serious infections among reported adverse events at transplant doses ^[8]. Intermittent low-dose protocols are designed to reduce this risk relative to continuous transplant dosing, but "reduce" isn't "eliminate," and there's no large human safety dataset specific to the intermittent longevity protocol. Mouth ulcers (stomatitis) are the most commonly reported side effect in both transplant patients and longevity users at lower doses. They're listed in the Rapamune prescribing information as a common adverse reaction and are consistently the top complaint in anecdotal longevity-user reports as well ^[8]. Metabolic effects are real and dose-related. Sirolimus is associated with elevated LDL cholesterol and triglycerides, and can worsen insulin resistance or unmask glucose intolerance in some patients, effects documented in the transplant literature and listed in the drug label ^[8]. This is a genuine irony worth sitting with: rapamycin extends lifespan in mice partly through metabolic pathways, yet in some humans it nudges lipid and glucose markers in the wrong direction. Longevity clinicians typically monitor lipid panels and fasting glucose periodically for this reason. Delayed wound healing is another labeled risk, relevant if you have upcoming surgery or dental work. Anyone starting sirolimus for any reason should tell every treating clinician and dentist beforehand.

Does the mTOR mechanism make the animal-to-human leap more believable?

It helps, but mechanism plausibility is not the same as proven human benefit, and it's worth being precise about what the mechanism actually predicts. mTOR (mechanistic target of rapamycin) is a cellular signaling hub that integrates nutrient and growth signals and drives cell growth, protein synthesis and proliferation when active. Rapamycin inhibits mTORC1 (and, with chronic high exposure, mTORC2). Reduced mTORC1 signaling is tied, across yeast, worms, flies and mice, to increased autophagy (cellular cleanup), reduced age-related protein aggregation, and effects on several of the biological "hallmarks of aging" described in the widely cited 2013 Cell review by Lopez-Otin and colleagues ^[12]. That cross-species conservation is part of why aging researchers take mTOR inhibition seriously as a target rather than dismissing it as species-specific noise. But conserved mechanism across short-lived organisms doesn't guarantee the same magnitude of effect, or any net lifespan effect, in a long-lived, genetically diverse species living in a modern human environment with different causes of death, different comorbidities, and decades-long exposure windows nobody has tested. Caloric restriction is the classic cautionary tale here: it reliably extends lifespan in mice and many other species through overlapping nutrient-sensing pathways, yet the human CALERIE trial found real metabolic and cardiovascular biomarker improvements from two years of caloric restriction but could not and did not claim it extends human lifespan, because that outcome wasn't and can't practically be measured in a trial of that length ^[13]. Rapamycin is in a similar epistemic position: mechanistically plausible, biomarker-supportive in early human data, lifespan-unproven in humans.

What would it take to actually prove rapamycin extends human lifespan?

A trial large enough, long enough, and controlled enough to detect a lifespan difference, which is a much higher bar than anything currently funded or running. Realistically, you'd need thousands of participants, likely starting in late middle age, followed for at least a decade, probably longer, with all-cause mortality as the primary endpoint, and a placebo arm, which raises real ethical questions once a drug is already prescribed off-label and believed by some clinicians to help. That combination of cost, duration and ethical complexity is why no one has done it and why most current research (like the PEARL trial) instead targets biomarkers of aging, frailty, or specific disease endpoints (like time to first age-related chronic disease) as more feasible surrogate outcomes ^[7]. Until a trial like that exists, the honest answer is that rapamycin's human longevity case rests on: excellent, repeated mouse survival data from a rigorous testing program ^[3][4][5]; a well-characterized human safety and pharmacology record from 25+ years of transplant use at different doses ^[8]; a biologically plausible and cross-species conserved mechanism ^[12]; and a small number of short human studies on immune and metabolic biomarkers, not survival ^[9]. That's a genuinely interesting stack of evidence. It is not proof of a human lifespan benefit, and anyone telling you otherwise is overstating the science.

Is rapamycin FDA-approved for anti-aging use?

No. Sirolimus is FDA-approved only for specific indications: preventing organ rejection in kidney transplant patients (as Rapamune, approved 1999) ^[8], treating a rare lung disease called lymphangioleiomyomatosis, and, in newer formulations, treating certain cancers (Fyarro, for malignant perivascular epithelioid cell tumor) and a skin condition called facial angiofibromas in tuberous sclerosis complex (Hyftor, a topical gel) . There is no FDA-approved indication for aging, longevity, or lifespan extension, for any formulation, at any dose. Every use of sirolimus for longevity purposes is off-label, meaning a licensed prescriber is legally allowed to prescribe an approved drug for an unapproved use based on their clinical judgment, but the FDA has not reviewed or approved evidence that it works for this purpose. Off-label prescribing is legal and common in medicine generally, but it means the FDA's approval process, which normally requires two adequate and well-controlled trials for the specific claimed benefit, has not been applied to the longevity claim at all.

How does the strength of mouse evidence compare across interventions tested for longevity?

Rapamycin is genuinely the standout among longevity compounds tested in the same rigorous mouse program, which is worth seeing side by side rather than taking on faith. | Intervention | ITP result (median lifespan) | Human lifespan trial completed? |

What should someone actually do with this evidence gap?

Treat the mouse data as a strong reason for interest and research funding, and treat any specific claim about your own personal life expectancy as unproven speculation, because that's what the actual evidence supports and nothing more. If you're already working with a prescriber on an off-label protocol, the practical, evidence-adjacent things to get right are dose, monitoring, and injection or reconstitution technique, since those affect real, measurable safety outcomes even though lifespan extension itself can't be measured in you personally. Our guides on Sirolimus Rx dosage, how to reconstitute Sirolimus Rx, Sirolimus Rx how to inject, Sirolimus Rx injection sites, and Sirolimus Rx cycle length cover the practical mechanics that a provider-reviewed protocol should walk you through. Sirolimus Rx works as a provider-reviewed pathway connecting patients with licensed prescribers and a fulfilling pharmacy partner for legitimate sirolimus prescriptions; it does not compound, manufacture, or make lifespan claims itself, and no reputable source should. If someone is selling you rapamycin with a promise about years added to your life, that promise is not backed by any completed human trial, full stop, regardless of how good the mouse data looks.

Frequently asked questions

Is sirolimus the same drug as rapamycin?

Yes. Sirolimus is the generic drug name; rapamycin is the original scientific name for the same molecule, first isolated from a soil bacterium on Easter Island in the 1970s. They're chemically identical. "Sirolimus" appears on prescription labels and FDA documents; "rapamycin" is more common in longevity research and aging biology literature.

Has any human study shown rapamycin extends lifespan?

No. No completed human study has measured or shown a lifespan-extension effect from rapamycin. The evidence for lifespan extension comes entirely from mouse and other animal studies, primarily the NIA's Interventions Testing Program. Human studies so far have looked at biomarkers, immune response, and short-term safety, not survival.

How much does rapamycin extend lifespan in mice?

NIA Interventions Testing Program data shows median lifespan increases ranging from about 9% (late-life-start dosing in the original 2009 cohort) up to roughly 23-26% in later cohorts with earlier starts and higher doses, with effects generally larger in female mice than male mice.

What is the NIA Interventions Testing Program?

It's a National Institute on Aging-funded research program, running since 2004 across three labs (Jackson Laboratory, University of Michigan, UT Health San Antonio), that tests candidate longevity compounds in genetically diverse mice using standardized protocols. Rapamycin is the only compound it has tested that has extended lifespan in every cohort and both sexes.

Why hasn't a human lifespan trial for rapamycin been done?

Cost, duration, and ethics. A trial capable of detecting a human lifespan effect would need thousands of participants followed for a decade or more, likely costing hundreds of millions of dollars, plus the ethical complication of a placebo arm withholding a drug some clinicians already believe helps. No funder has taken this on.

Is off-label rapamycin for longevity legal?

Yes, in the sense that licensed prescribers can legally prescribe FDA-approved drugs for unapproved uses based on clinical judgment. But the FDA has not approved, reviewed, or endorsed rapamycin for longevity or anti-aging use at any dose or schedule; every longevity use is off-label.

What are the biggest risks of taking sirolimus for longevity?

Immunosuppression and higher infection risk, mouth ulcers (stomatitis, the most commonly reported side effect), elevated cholesterol and triglycerides, potential worsening of blood glucose control, and delayed wound healing. These are documented in the FDA label for transplant-dose sirolimus; intermittent low-dose longevity protocols aim to reduce but not eliminate these risks.

Does intermittent dosing avoid the side effects of daily rapamycin?

It may reduce some risks based on mouse studies (Bitto et al., 2016) showing intermittent high-dose rapamycin extended mouse lifespan with less continuous immune suppression than daily dosing. But no completed human study has directly compared intermittent versus continuous longevity dosing for safety or benefit over years.

What is the PEARL trial and does it prove rapamycin works in humans?

PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is an ongoing human trial measuring biomarkers like frailty index and biological age proxies over roughly one to four years. It does not measure lifespan and hasn't proven a longevity benefit; it's biomarker research, a different and more feasible question than survival.

Is rapamycin FDA-approved for anything?

Yes, for specific conditions unrelated to aging: preventing kidney transplant rejection (Rapamune, since 1999), a rare lung disease called lymphangioleiomyomatosis, certain cancers (Fyarro), and facial angiofibromas in tuberous sclerosis (Hyftor, topical). It has no FDA approval for anti-aging or lifespan extension.

How does rapamycin's mouse evidence compare to metformin's for longevity?

Rapamycin has shown consistent, reproducible lifespan extension across every NIA ITP cohort and both sexes. Metformin has not shown significant lifespan extension in ITP mouse testing, despite its popularity in longevity discussions. Neither drug has a completed human lifespan trial; the proposed TAME trial for metformin has not been completed or fully funded.

Can the mouse dose of rapamycin be directly converted to a human dose?

Not simply. Mouse ITP studies used continuous dietary dosing calibrated to mouse body size and metabolism, while human off-label longevity protocols mostly use intermittent weekly or biweekly dosing based on different pharmacology and reasoning. There's no validated direct conversion, and human dosing decisions rely on clinical extrapolation, not a proven translation formula.

Sources

1. NIH National Center for Biotechnology Information (NCBI Bookshelf): Rapamycin was isolated from Streptomyces hygroscopicus found in soil samples from Easter Island (Rapa Nui)
2. FDA Drug Approvals Database: Rapamune (sirolimus) FDA approval history and application details
3. National Institute on Aging Interventions Testing Program: Description and structure of the NIA-funded ITP testing longevity interventions across three labs since 2004
4. Harrison et al., Nature 2009: Rapamycin extended median lifespan in mice starting treatment at 20 months of age, by 9% in males and 13% in females
5. Miller et al., Journals of Gerontology Series A, 2011 (PMID 21525125): Later ITP cohorts with earlier-start, higher-dose rapamycin showed larger lifespan extension, up to roughly 23-26%
6. National Institute on Aging, Rapamycin research overview: Rapamycin has extended lifespan across multiple model organisms including yeast, worms, and flies
7. AKG Foundation / PEARL Trial Registration, ClinicalTrials.gov: The PEARL trial measures frailty index and biological aging biomarkers, not lifespan, over a defined follow-up period
8. Mannick et al., Science Translational Medicine 2014: Low-dose mTOR inhibitor (RAD001) improved influenza vaccine response in adults over 65 in a short-term study
9. Bitto et al., eLife 2016: Intermittent, high-dose rapamycin extended mouse lifespan and improved healthspan measures with reduced continuous immunosuppression compared to daily dosing
10. Lopez-Otin et al., Cell 2013: Deregulated nutrient sensing, including mTOR signaling, is described as one of the conserved hallmarks of aging across species
11. CALERIE Trial results, published in The Lancet Diabetes & Endocrinology: Two years of caloric restriction in humans improved metabolic and cardiovascular biomarkers but did not and could not measure lifespan extension
12. FDA approval announcement for Fyarro: Fyarro (sirolimus protein-bound) is FDA-approved for malignant perivascular epithelioid cell tumor, distinct from anti-aging use
13. Strong et al., Aging Cell 2016 (PMID 26988075): Comparative ITP results showing metformin and resveratrol did not significantly extend mouse lifespan while acarbose and rapamycin did